News

Saanich biotech company secures $52M US for global drug study

A biotech company based out of the Vancouver Island Technology Park in Saanich received $52 million US earlier this month to help fund a clinical study for their drug that aims to treat a kidney-based form of lupus.

Michael Martin, COO of Aurinia Pharmaceuticals Inc., says the private investment comes as the company aims to start a lengthy global clinical study for voclosporin.

“The study is basically looking at active flaring lupus nephritis patients – these are very sick patients. And we’re going to try to induce remission, primarily driven by reducing the amount of protein in a patient’s urine,” he said.

Martin says now that the money is secured, they expect the first patient study to begin in the spring. There will be 60 sites in 25 countries that will test the effectiveness.

More than 2,000 patients have undergone trials of voclosporin. For more information, visit auriniapharma.com.

editor@saanichnews.com

We encourage an open exchange of ideas on this story's topic, but we ask you to follow our guidelines for respecting community standards. Personal attacks, inappropriate language, and off-topic comments may be removed, and comment privileges revoked, per our Terms of Use. Please see our FAQ if you have questions or concerns about using Facebook to comment.

You might like ...

Housing money reinstated by Victoria council
 
Farrah Fawcett dies age 62
 
Council delegations have plenty to say
Search and rescue veteran in Alberni retires after 47 years
 
Qualicum adds electric car to its fleet
 
Spill could kill tourism, shellfish, say Parksville protesters
Home economics classes prepare feast for students
 
The Week — Dec. 22
 
Who wants to be a mayor?

Community Events, October 2014

Add an Event

Read the latest eEdition

Browse the print edition page by page, including stories and ads.

Oct 17 edition online now. Browse the archives.